Temelimab for MS and SARS-CoV-2: Could it be a double-edged blessing?
作者信息
Mouliou Dimitra S, Dardiotis Efthimios
机构信息
Department of Neurology, Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa 41100, Greece.
Department of Neurology, Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa 41100, Greece.
出版信息
Mult Scler Relat Disord. 2022 Aug;64:103938. doi: 10.1016/j.msard.2022.103938. Epub 2022 Jun 6.
Abstract
摘要
相似文献
1
Temelimab for MS and SARS-CoV-2: Could it be a double-edged blessing?替麦利单抗用于治疗多发性硬化症和新冠病毒：它会是一把双刃剑吗？
Mult Scler Relat Disord. 2022 Aug;64:103938. doi: 10.1016/j.msard.2022.103938. Epub 2022 Jun 6.
2
Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab.奥法妥木单抗治疗复发性多发性硬化症患者中 SARS-CoV-2 免疫球蛋白 M 和 G 抗体的产生。
Mult Scler Relat Disord. 2021 Apr;49:102777. doi: 10.1016/j.msard.2021.102777. Epub 2021 Jan 19.
3
Dupilumab, severe asthma airway responses, and SARS-CoV-2 serology.度普利尤单抗、重度哮喘气道反应与严重急性呼吸综合征冠状病毒2血清学
Allergy. 2021 Mar;76(3):957-958. doi: 10.1111/all.14534. Epub 2020 Aug 24.
4
Importance of eculizumab treatment in recurrence of atypical hemolytic uremic syndrome during the SARS-CoV-2 pandemic.依库珠单抗治疗在严重急性呼吸综合征冠状病毒2大流行期间非典型溶血性尿毒症综合征复发中的重要性。
Int Urol Nephrol. 2022 Feb;54(2):459-460. doi: 10.1007/s11255-021-02890-y. Epub 2021 May 18.
5
Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.白细胞介素-6受体拮抗剂疗法治疗肾移植受者中由SARS-CoV-2驱动的炎症综合征。
Transpl Infect Dis. 2020 Aug;22(4):e13326. doi: 10.1111/tid.13326. Epub 2020 Jun 5.
6
Hemolytic crisis in a patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case report.1例接受依库珠单抗治疗的阵发性睡眠性血红蛋白尿患者发生溶血性危机，可能由SARS-CoV-2（新冠病毒病）触发：病例报告
Ann Hematol. 2021 Mar;100(3):841-842. doi: 10.1007/s00277-020-04318-6. Epub 2020 Nov 10.
7
Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors' reply.托珠单抗用于新型冠状病毒肺炎的理论依据与证据：一项系统评价。作者回复
Pulmonology. 2021 Jan-Feb;27(1):87-88. doi: 10.1016/j.pulmoe.2020.10.003. Epub 2020 Oct 21.
8
Benralizumab: A potential tailored treatment for life-threatening DRESS in the COVID-19 era.贝那利珠单抗：新冠疫情时代治疗危及生命的药物超敏反应伴嗜酸性粒细胞增多和系统症状（DRESS）的一种潜在定制疗法。
J Allergy Clin Immunol Pract. 2021 Sep;9(9):3529-3531.e1. doi: 10.1016/j.jaip.2021.06.047. Epub 2021 Jul 15.
9
Temelimab, an IgG4 Anti-Human Endogenous Retrovirus Monoclonal Antibody: An Early Development Safety Review.替利珠单抗，一种 IgG4 抗人类内源性逆转录病毒单克隆抗体：早期开发安全性综述。
Drug Saf. 2020 Dec;43(12):1287-1296. doi: 10.1007/s40264-020-00988-3.
10
Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab.一名接受奥瑞珠单抗治疗的患者在接种辉瑞新冠疫苗后抗新冠病毒刺突蛋白抗体反应呈阴性
J Neurol. 2021 Oct;268(10):3592-3594. doi: 10.1007/s00415-021-10463-3. Epub 2021 Feb 27.
引用本文的文献
1
COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches.COVID-19 与贫血和血液系统恶性肿瘤患者：风险因素、临床指南和新兴治疗方法。
Cell Commun Signal. 2024 Feb 15;22(1):126. doi: 10.1186/s12964-023-01316-9.
2
C-Reactive Protein: Pathophysiology, Diagnosis, False Test Results and a Novel Diagnostic Algorithm for Clinicians.C反应蛋白：病理生理学、诊断、检测结果假阳性及面向临床医生的新型诊断算法
Diseases. 2023 Sep 28;11(4):132. doi: 10.3390/diseases11040132.
3
Etiopathogenic theories about long COVID.关于长期新冠的病因学理论。
World J Virol. 2023 Jun 25;12(3):204-208. doi: 10.5501/wjv.v12.i3.204.
4
The Deceptive COVID-19: Lessons from Common Molecular Diagnostics and a Novel Plan for the Prevention of the Next Pandemic.具有欺骗性的新冠病毒：普通分子诊断带来的教训以及预防下一次大流行的新计划
Diseases. 2023 Jan 28;11(1):20. doi: 10.3390/diseases11010020.
Zotero 插件